irbesartan

Subscribe to Selected New Research on irbesartan

412 relevant articles (56 outcomes, 181 trials/studies) found for this Drug

Description: a nonpeptide At(1) subtype angiotensin II receptor antagonist; structure given in first source

Also Known As:

2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one; Aprovel; Avapro; BMS 186295; BMS Brand of Irbesartan; BMS-186295; Bristol Myers Brand of Irbesartan; Karvea; SR 47436; SR-47436; Sanofi Winthrop Brand of Irbesartan; 1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Cyclic Hydrocarbons: 2

Aromatic Hydrocarbons: 115

Benzene Derivatives: 9

Biphenyl Compounds: 1

irbesartan: 412

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Azoles: 224

Tetrazoles: 5

irbesartan: 412

Experts

1.	Kahan, Thomas: 13 articles (07/2008 - 04/2002)
2.	Malmqvist, Karin: 12 articles (09/2007 - 04/2002)
3.	Palmer, Andrew J: 9 articles (05/2008 - 07/2003)
4.	Lind, Lars: 8 articles (07/2008 - 04/2002)
5.	Melhus, Håkan: 7 articles (07/2008 - 04/2002)
6.	Kurland, Lisa: 7 articles (07/2008 - 04/2002)
7.	Rodby, Roger A: 7 articles (11/2006 - 07/2003)
8.	Nyström, Fredrik: 7 articles (03/2004 - 04/2002)
9.	Karlsson, Julia: 6 articles (03/2004 - 04/2002)
10.	Annemans, Lieven: 5 articles (05/2008 - 07/2003)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/2008 - "Furthermore, the proportion of patients with severe hypertension achieving controlled BP of < 140/90 mmHg was significantly greater at all timepoints of the trial compared with irbesartan monotherapy" 07/01/2004 - "In conclusion, treatment of hypertension with irbesartan resulted in a significant reduction in the voltage criteria for LVH, although an effect on LVM was only seen in subjects with high baseline LVM" 09/01/2008 - "The results showed that irbesartan administered 100 mg once daily was well tolerated in the treatment of essential hypertension and was effective in producing sustained 24-h BP control" 10/01/2005 - "The objective of this study was to test the presence of the CYP2C93 allelic variant in the Chinese population and to investigate the association of this variant with both metabolism and therapeutic efficacy of irbesartan on essential hypertension" 05/01/1999 - "Irbesartan is effective in the elderly and non-elderly, men and women and in cases of mild and severe hypertension" Get all the results and reference details, order at left...*
2.	Proteinuria 11/01/2002 - "The IRMA study showed that irbesartan is more effective than conventional therapy in preventing the development of clinical proteinuria and in favoring the regression to normoalbuminuria for comparable BP control in patients with incipient nephropathy" 12/01/1998 - "Also, patients randomized to receive the AngII receptor antagonist irbesartan for 28 d had lower proteinuria (55% change from baseline) and fractional clearance of albumin at the end of the treatment period with similar renal hemodynamic changes" 03/01/2005 - "The Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA) Study showed that, as compared with conventional therapy, irbesartan is better at preventing the development of clinical proteinuria and at restoring normoalbuminuria for comparable BP control in patients with incipient nephropathy" 03/01/2005 - "In conclusion, the results of the Program for Irbesartan Mortality and Morbidity Evaluation demonstrate that irbesartan significantly prevents the development of clinical proteinuria in individuals with microalbuminuria and delays the progression of nephropathy in individuals with proteinuria" 02/01/2005 - "Proteinuria reduction in the first 12 months of therapy with irbesartan is associated with 36% of the total renoprotective effect observed" Get all the results and reference details, order at left...
3.	Heart Failure 04/01/1999 - "Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure." 10/01/2005 - "METHODS AND RESULTS: The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) is enrolling 4100 subjects with HF-PSF to evaluate whether 300 mg irbesartan is superior to placebo in reducing mortality and prespecified categories of cardiovascular hospitalizations" 12/01/1997 - "Preliminary studies evaluating the efficacy of irbesartan in patients with heart failure have produced encouraging results" 02/01/2008 - "BACKGROUND: We describe the baseline characteristics of subjects randomised in the largest placebo-controlled, morbidity-mortality trial to date in patients with heart failure and preserved ejection fraction - the irbesartan in heart failure with preserved systolic function trial (I-PRESERVE)" 10/01/2005 - "The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design." Get all the results and reference details, order at left...
4.	Syndrome 01/01/2007 - "RESULTS: Use of irbesartan 300 mg/day as monotherapy in previously uncontrolled patients resulted in a significant reduction in SBP/DBP (-26.8/-13.3mm Hg, p < 0.0001), which was comparable to the subgroup of patients with the metabolic syndrome (-26.3/-13.0mm Hg, p < 0.0001 vs baseline)" 01/01/2007 - "RESULTS: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome" 09/01/2008 - "The aim of the present study was to determine the influence of irbesartan on ED in patients with a metabolic syndrome" 01/01/2007 - "We set out to investigate the role in clinical practice of irbesartan in improving BP in uncontrolled hypertensive patients with a particular focus on patients with the metabolic syndrome through analysis of data from a post-marketing surveillance study" 01/01/2007 - "A total of 750 primary care physicians evaluated up to 5 subsequent patients with metabolic syndrome (58.9% diabetic), in whom irbesartan therapy was newly initiated (87%) or continued (13%)" Get all the results and reference details, order at left...
5.	Diabetic Nephropathies (Diabetic Nephropathy) 10/01/2007 - "Transition probabilities determining nephropathy progression were taken from the Irbesartan in Reduction of Microalbuminuria-2 study, Irbesartan in Diabetic Nephropathy Trial and other published sources" 09/01/2007 - "METHODS: 218 patients at high risk of cardiovascular events (from the "Irbesartan in Diabetic Nephropathy Trial" [IDNT] cohort) with type 2 diabetes and nephropathy (mean age 61 +/- 6,4 years, 68 female, 150 male) were followed for a mean of 2.2 years" 11/01/2006 - "Probabilities came from the Irbesartan in Reduction of Microalbuminuria-2 study, Irbesartan in Diabetic Nephropathy Trial and other sources" 10/01/2006 - "METHODS: Four hundred fifty patients with type 2 diabetes and nephropathy from the Irbesartan in Diabetic Nephropathy Trial cohort (mean age, 58 +/- 8.2 years; 137 women, 313 men) with a mean glomerular filtration rate of 48.2 mL/min (0.80 mL/s; Modification of Diet in Renal Disease formula) were followed up for 2.6 years" 08/04/2006 - "BACKGROUND AND OBJECTIVE: It was the aim of this study to project the long-term clinical and cost outcomes of irbesartan treatment, based on data from the irbesartan in Reduction of Microalbuminuria-2 (IRMA-2) study and the irbesartan in Diabetic Nephropathy Trial (IDNT), in hypertensive patients with type 2 diabetes and renal disease in Germany" Get all the results and reference details, order at left...
109 Diseases and 412 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Losartan (Cozaar)
2.	Hydrochlorothiazide (Esidrix)
3.	Angiotensins
4.	Angiotensin II
5.	Amlodipine (Norvasc)
6.	Enalapril
7.	Captopril (Capoten)
8.	Ramipril (Altace)
9.	Angiotensin Receptors (Angiotensin II Receptor)
10.	irbesartan
167 Drugs and Important Bio-Agents and 318 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Exercise (Aerobic Exercise)
2.	Kidney Transplantation
3.	Nephrectomy
4.	Renal Replacement Therapy (Therapies, Renal Replacement)
5.	Renal Dialysis (Hemodialysis)
13 Therapies and Procedures and 15 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>